Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Development pf antibacterials differs in several important ways from drug development in other areas, and the lack of standard dose-finding is just one of them. Dose-finding in its most basic form involves ascending amounts of drug for efficacy and safety; Continue reading Efficacy and Treatment Duration: Where is the Tipping Point?
We will get to the new Hoberman study[1] in a moment, but first a bit of background. AOM, AECS and AECB were labeled indications for antibiotics in the 80s and 90s but were summarily thrown out from the indication catalogue Continue reading Is the AOM Indication Making a Come-Back?
The cartilage damage caused by fluoroquinolones in juvenile beagle dogs is not subtle: blister formation and erosions occur in a dose-dependent fashion resulting in reversible cartilage damage. These lesions can be seen not just histologically but even macroscopically. The animals Continue reading The Futile Quest of Proofing a Negative in the Presence of Overwhelming Absence of Harm